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Para-aminosalicylic acid (PAS) is a group 4 anti-tuberculosis agent (1). It targets folate metabolism as 41 
shown in Fig. S1, which also summarises the known resistance mechanisms to this pro-drug (2). 42 
Recently, we reported a multidrug-resistant (MDR) Mycobacterium tuberculosis Beijing strain 43 
harbouring a deletion of both dfrA and thyA from Australia (Fig. 1A and Table S1) (3). Since then, we 44 
have found deletions affecting both genes in five further MDR Beijing strains (two isolated in Australia 45 
and three from Peru) and one extensively drug-resistant (XDR) Beijing strain from China. The 46 
Australian MDR strains were recovered from three patients with no apparent epidemiological links 47 
and were likely infected in their country of origin (Table S1). The three Peruvian isolates were closely 48 
related and consequently shared the same deletion, whereas the remaining strains were distantly 49 
related and had deletions that differed in size (Fig. 1A). Consequently, these five distinct deletions 50 
were acquired independently, which can be a signal for positive selection of resistance mechanisms. 51 
In line with this hypothesis, the strains from Australia and China were PAS resistant when tested with 52 
the BACTEC MGIT 960 system and on Löwenstein-Jensen medium, respectively (Supplementary 53 
Methods). Two out of the three Peruvian deletion mutants were also PAS resistant on 7H10 medium 54 
at 8 μg/mL, whereas the two closely related ancestral wild-type strains were susceptible (Fig. 1B). We 55 
were unable to retest the strains at 2 μg/mL, the recommended critical concentration by the Clinical 56 
and Laboratory Standards Institute and World Health Organization, which would have clarified 57 
whether the susceptible result for the third deletion mutant was an artefact (1, 4). 58 
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The observation that dfrA could be deleted was remarkable in light of our current 59 
understanding of folate metabolism in M. tuberculosis. Two studies suggested that dfrA is essential in 60 
vitro in the H37Rv laboratory strain (5, 6). More recently, it was shown that dfrA is conditionally 61 
essential and can only be knocked out in H37Rv if Rv2671 is over-expressed in trans, presumably due 62 
to its much lower dihydrofolate reductase activity compared with DfrA (7, 8). Our in silico analysis of 63 
the seven dfrA-thyA double deletion mutants did not reveal any known Rv2671 mutations (Table S1), 64 
such as the G to A upstream mutation at position -12 that results in its over-expression and 65 
consequently confers PAS resistance (this mutation was incorrectly referred to as affecting position -66 
11 in two of our prior studies (7, 9)). Assuming that no other pertinent differences exist that are 67 
specific to the Beijing genotype relative to H37Rv or that a yet unknown acquired mutation elsewhere 68 
in the genome were present that resulted in the over-expression of Rv2671, we propose that this 69 
apparent contradiction can be reconciled if the essentiality of dfrA was not only dependent on the 70 
expression level of Rv2671, but also on the presence of wild-type thyA. The fact that thyA was deleted 71 
in all seven dfrA mutants meant that only the second thymidylate synthase, encoded by the essential 72 
thyX, was active in these strains (Fig. S1). Contrary to ThyA, ThyX generates tetrahydrofolate rather 73 
than dihydrofolate upon catalysis and therefore does not require high dihydrofolate reductase 74 
activity to provide sufficient levels of tetrahydrofolate (2). This is in line with the fact that dfrA is not 75 
required in bacterial species that lack thyA (10). Consequently, Rv2671 appeared to be sufficient to 76 
sustain growth, even without being over-expressed in these deletion mutants. It should therefore be 77 
possible to knock out dfrA in strains of M. tuberculosis with inactive thyA. Moreover, the adjacent 78 
location of thyA and dfrA in genome should make their simultaneous deletion possible (Fig. 1A). 79 
Interestingly, all but one of the deletion mutants also convergently acquired mutations 80 
upstream of thyX compared to the two closely related Peruvian control strains (Fig. 1B & Table S1) 81 
(11). In fact, the cluster of three Peruvian strains and two of the unrelated Australian strains shared 82 
the same C to T upstream mutation at position -16 that has been previously found to be associated 83 
with resistance to several drugs and experimentally shown to result in the over-expression of thyX 84 
(12). It is therefore plausible that these changes compensated for the reduced expression levels and 85 
enzymatic activity of ThyX compared to ThyA (11, 13).  Based on our data, however, it was not 86 
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possible to deduce whether the thyX mutations were acquired after the deletions of thyA and dfrA in 87 
each strain, as would be expected with compensatory mutations (11). 88 
In summary, these data demonstrated that the folate metabolism and the genetic basis of 89 
PAS resistance are more complex than previously appreciated, which is relevant for the development 90 
of novel DfrA and ThyX inibitors and potentially the use of trimethoprim-sulfamethoxazole to treat 91 
drug-resistant tuberculosis (Fig. S1) (14-25). Although deletions are often excluded from large-scale 92 
whole genome studies owing to the limited read lengths next-generation sequencers and the fact that 93 
algorithms are optimised for SNP calling, this study highlighted that deletions can no longer be 94 
ignored (3, 26). 95 
  96 
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Fig. 1. Analysis of dfrA and thyA deletion strains, all of which tested PAS resistant, with the exception 97 
of PH107_CA033M_1. (a) Diagram of deletions in seven clinical strains compared with the wild-type 98 
H37Rv laboratory strain. The scale at the top corresponds to the genome position in H37Rv. The letter 99 
in parentheses denotes the country of isolation (Australia (A), China (C), and Peru (P)). Mtb97 was 100 
reported previously (3). (b) Maximum likelihood tree based on whole-genome data of the three 101 
Peruvian deletion mutants, which also share a mutation upstream of thyX that is also present in 102 
Mtb97 and Mtb78 (Table S1), and two closely related wild-type strains, which were PAS susceptible. 103 
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